The pathogenesis and potential therapeutic targets of metaflammation in NAFLD.

"Metaflammation," proposed by Hotamisligil in 2006, refers to a chronic low-grade inflammation triggered by metabolic factors such as excessive nutrition and energy, persisting at subacute levels over an extended period. Immune cells infiltrate the inflammatory site, leading to enhanced expression or activity of various inflammatory molecules and subsequent inflammatory damage. Recent research on metabolic-related fatty liver disease has revealed that modern metaflammation plays a pivotal role in the pathogenesis of NAFLD. The associated inflammatory pathways offer promising prospects for the development of targeted drugs. This article provides an updated review on the advancements in metaflammation within NAFLD. [ABSTRACT FROM AUTHOR]